Clinical trials
Chronic Hepatitis B Infection clinical trials
Below are recruiting chronic hepatitis b infection clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05956379Enrolling by invitation
Exercise and monitoring study for chronic hepatitis B with fatty liver
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
Taipei, Zhongzheng Dist.Ages 18–70 - NCT06876467Recruiting
Study of immune response to hepatitis B vaccine
This study looks at how your body's cells respond after getting a hepatitis B vaccine. It may help researchers understand how well the vaccine works.
ParisAges 18 years+ - NCT04025944Recruiting
Study of long-term hepatitis B or C infection
This study looks at people with hepatitis B or C infections that have lasted more than 6 months. It aims to better understand long-term management and how treatments may help over time.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02699736Enrolling by invitation
HIV and hepatitis C study in European adults
This study follows people living with HIV who also have hepatitis C antibodies, to better understand how HIV and hepatitis C affect health over time. You may be able to join if you meet the age and enrollment requirements, even if your hepatitis C virus level is currently undetectable.
Buenos AiresAges 16 years+ - NCT07096193RecruitingPhase 1/Phase 2
Study of GS-4321 for chronic hepatitis delta
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
Anaheim, CaliforniaAges 18–69 - NCT03825458Recruiting
Study tracking hepatitis B viral RNA in blood
This study builds a group of people to measure small hepatitis B “viral RNA” signals in the blood. The goal is to see if these measurements could help researchers find a functional cure and better understand who may respond over time.
LyonAges 18 years+ - NCT06659588Recruiting
Study of chronic hepatitis risk in people with immune weaknesses
This study looks at people with certain immune system weaknesses to see if they are at risk for chronic hepatitis caused by a virus in the gut. Researchers want to understand how the immune system affects this infection.
ParisAges Any age - NCT07275554Recruiting
Gene patterns and risk prediction in hepatitis B liver failure
This study looks at how gene changes (methylation) in people with hepatitis B-related liver failure may predict how well they will do. It aims to create a risk score to guide treatment.
Jinan, ShandongAges 18 years+ - NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+ - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05583006Recruiting
Switch from entecavir to tenofovir for chronic hepatitis B
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Taichung, TaiwanAges 20 years+ - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT06323681Recruiting
Lower-dose interferon for chronic hepatitis B patients who've tried it before
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06364930RecruitingPhase 4
SGLT2 inhibitor to prevent liver problems in hepatitis B and diabetes
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
Hong KongAges 18 years+ - NCT06457477Recruiting
PD-1 antibody and peginterferon for chronic hepatitis B
This trial tests a combination of a PD-1 antibody (a type of immunotherapy) and peginterferon alpha for people with chronic hepatitis B whose virus is already under control but whose surface antigen levels haven't improved much with standard therapy. It aims to see if the combo can help reduce the hepatitis B surface antigen further.
Beijing, Beijing MunicipalityAges 18–65 - NCT06550622Recruiting
Better Detection of Hepatitis B Virus After Treatment
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07275918RecruitingPhase 1
Study of SA1211 injection for chronic hepatitis B
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
Changchun, JilinAges 18–65 - NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT07668934Enrolling by invitationPhase 4
TAF for early and middle pregnancy with chronic hepatitis B
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
Guangzhou, GuangdongAges 20–40 - NCT06777173Enrolling by invitation
Antiviral and Immunotherapy for Chronic Hepatitis B
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
BeijingAges 18–65 - NCT06668727RecruitingPhase 1
Testing a new antibody for hepatitis B safety
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Aarhus NAges 18–70 - NCT05403047RecruitingPhase 4
Preventing mom-to-baby hepatitis B with tenofovir
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
TokonbéréAges 16 years+ - NCT07542951Enrolling by invitationPhase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
Guangzhou, GuangdongAges 20–40
Hear when a new Chronic Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis b infection?
- Yes. Clin2 currently lists 161 recruiting chronic hepatitis b infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis b infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis b infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.